Reference
Scientific data
Publications
Products

Home page
CNR LOGOItalian National Research Council LOGO PFITargeted Project on Ageing

Research Unit Director: BATTISTIN Leontino

Address: Università di Padova - Istituto Malattie Nervose e Mentali - Facoltà Medicina e Chirurgia
Via Giustiniani, 5 - 35128 - Padova
tel.: 049-8213600/01 - fax: 049-8751770

Scientific informations

Subproject2 Italian Longitudinal Study of Ageing

Title of research

Longitudinal study of dementias.

Keywords
Epidemiology Dementia Brain aging SPECT/PET

Aims

Evaluation of epidemiological data of Alzheimer's disease, multi-infarct dementia and Parkinson-dementia in the longitudinal study population.
Evaluation of the efficacy of brain imaging studies (PET and SPECT) in the clinical differential diagnosis of the dementing syndromes.

Scientific activity

Epidemiological study - neurologic evaluation.

Epidemiologic and neurological evaluation has been performed in 423 subjects (94 within the protocol for dementia, 52 within the protocol for parkinsonian syndromes, 144 within the protocol for symmetric polineuropathy, 62 within the protocol for cerebrovascular diseases).

Functional neuroimaging in dementia and Parkinson's disease.

We used SPECT with perfusion (HM-PAO, ECD) and D2 receptors (IBZM) tracers and, in some patients, PET with 18F-fluorodeoxyglucose. In dementia, neuroimaging studies addressed two topics: 1- evaluation of SPECT and PET findings in terms of diagnostic specificity and sensibility, 2- D2 receptors study in DAT in relation to extrapyramidal symptoms. Striatal D2 receptors imaging in Parkinson's disease has been evaluated in relation to: 1- therapeutic response to L-Dopa in idiopathic Parkinson's disease, 2- differential diagnosis of idiopathic Parkinson's disease and parkinsonisms (in this case, together with cortical metabolic and perfusion findings).

Scientific results

We performed SPECT with a perfusion tracer and a D2 receptor ligand in Alzheimer's dementia patients and in patients with a clinical diagnosis of frontal lobe dementia. Whereas HM-PAO SPECT could not separate the two groups of patients, IBZM SPECT showed a significantly reduced uptake in frontal regions of the group of patients with frontal lobe degeneration.

IBZM SPECT was used to determine D2 receptors number in basal ganglia regions of Alzheimer patients without overt extrapyramidal symptomatology. Caudate and putamen D2 receptors number was significantly reduced as compared to age-matched control subjects.

In Parkinson's dissease patients, striatal D2 receptors number was determined in groups of patients separated on the basis of their response to therapy. Significantly reduced IBZM striatal uptake was found only in the group of patients with a fluctuating response to levodopa.

Reference
Scientific data
Publications
Products

Home page
 Publications

Publications on Journals cited by Current Contents
  1. FRISONI GB, BIANCHETTI A, TRABUCCHI M, PIZZOLATO G, SPECT and dementia, Neurology, 1992, 42: 1850-1851
  2. PIZZOLATO G, CHIERICHETTI F, ROSSATO A, BRIANI C, DAM M, BORSATO N, SAITTA B, ZANCO P, FERLIN G, BATTISTIN L, Dopamine receptor SPET imaging in Parkinson's disease: a [123I]-IBZM and [99mTc]-HM-PAO study, Europ. Neurol., 1993, 33: 143-148
  3. FRISONI GB, TRABUCCHI M, PIZZOLATO G, COLE AJ, Frontal lobe dementia, Int. J. Geriat. Psychiatry, 1993, 8: 357-358
  4. FRISONI GB, PIZZOLATO G, BIANCHETTI A, CHIERICHETTI F, FERLIN G, BATTISTIN L, TRABUCCHI M, Single photon emission computed tomography with [99Tc]-HM-PAO and [123I]-IBZM in Alzheimer's disease and dementia of frontal type: preliminary results, Acta Neurol. Scand., 1994, 89: 199-203
  5. FRISONI GB, PIZZOLATO G, ZANETTI O, BIANCHETTI A, CHIERICHETTI F, TRABUCCHI M, Corticobasal degeneration: neuropsychological assessment and dopamine D2 receptor SPECT analysis, Eur. Neurol., 1995, 35: 50-54
  6. PIZZOLATO G, CHIERICHETTI F, ROSSATO A, CAGNIN A, FABBRI M, DAM M, FERLIN G, BATTISTIN L, Alterations of striatal dopamine D2 receptors contribute to deteriorated response to L-Dopa in Parkinson's disease: a [123I]-IBZM SPET study, J. Neural Transm., 1995, 45: 113-122
  7. FRISONI GB, PIZZOLATO G, GEROLDI C, ROSSATO A, BIANCHETTI A, TRABUCCHI M, Dementia of the frontal type: neuropsychological and [99Tc]-HM-PAO SPET features, J. Geriatr. Psychiatry Neurol., 1995, 8: 42-48
  8. PIZZOLATO G, CAGNIN A, ROSSATO A, CHIERICHETTI F, FABBRI M, DAM M, FERLIN G, BATTISTIN L, Striatal dopamine D2 receptors alterations and responses to L-DOPA in Parkinson's disease: a [123I]-IBZM SPET study, Adv. Neurol., 1996, 69: 467-473
  9. DAM M, TONIN P, CASSON S, BRACCO F, PIRON L, PIZZOLATO G, BATTISTIN L, Effects of conventional and sensory-enhanced physiotherapy on disability of Parkinson's disease patients, Adv. Neurol., 1996, 69: 551-555
  10. DAM M, TONIN P, DE BONI A, PIZZOLATO G, CASSON S, ERMANI M, FREO U, PIRON L, BATTISTIN L, The effects of fluoexetine and maprolitine on functional recovery in post-stroke hemiplegic patients undergoing rehabilitation therapy, Stroke, 1996, 27: 1211-1214
  11. PIZZOLATO G, CHIERICHETTI F, FABBRI M, CAGNIN A, DAM M, FERLIN G, BATTISTIN L , Reduced striatal dopamine receptors in Alzheimer's disease: single photon emission tomography study with the D2 tracer [123I]-IBZM, Neurology, 1996, 47: 1065-1068
  12. GEROLDI C, FRISONO GB, BELTRAMELLO A, WEISS C, BIANCHETTI A, PIZZOLATO G, FERLIN G, TRABUCCHI M, Magnetic resonance and single-photon emission tomography findings in a pair of twins discordant for Alzheimer's disease, J. Neuroimaging, 1996, 6: 76-80
Publications on other journals
  1. FRISONI GB, BIANCHETTI A, PIZZOLATO G, FERLIN G, BATTISTIN L, TRABUCCHI M, Functional imaging ([99mTc]-HM-PAO SPECT) and clinical findings in the differentiation of Alzheimer's disease and dementia of frontal type, Neurobiology of Aging, 1992, 13: S16
  2. PIZZOLATO G, ROSSATO A, DAM M, CHIERICHETTI F, BRIANI C, FERLIN G, BATTISTIN L, Single photon emission computed tomography (SPECT) imaging of dopamine D2 receptors in Parkinson's disease (PD): relation to therapeutic response, Neurobiology og Aging, 1992, 13: S17
  3. PIZZOLATO G, PONZA I, DAM M, ROSSATO A, BRIANI C, CHIERICHETTI F, BORSATO N, FERLIN G, BATTISTIN L, SPECT imaging of the brain in dementia: follow-up evaluation, Neurobiology of Aging, 1992, 13: S21-S22
  4. ROSSATO A, PIZZOLATO G, CHIERICHETTI F, BRIANI C, DAM M, BRACCO F, FERLIN G, BATTISTIN L, [123I]-IBZM SPET imaging of D2 receptors in Parkinson's disease: relation to therapeutic response, New Trends Clin. Neuropharm., 1992, 4: 63-67
  5. CHIERICHETTI F, PIZZOLATO G, BORSATO N, SAITTA B, ROSSATO A, BATTISTIN L, FERLIN G, Dopamine receptor SPET in the study of parkinsonian patients, J. Nucl. Biol. Med., 1992, 36: 107-108
  6. FRISONI GB, PIZZOLATO G, BIANCHETTI A, FERLIN G, BATTISTIN L, TRABUCCHI M, Cortical D2 dopaminergic receptors in Alzheimer's disease and dementia of frontal type, Adv. Biosciences, 1993, 87: 27-28
  7. FRISONI GB, PIZZOLATO G, ZANETTI O, BIANCHETTI A, FERLIN G, TRABUCCHI M, Corticobasal degeneration: dopamine D2 receptor SPECT analysis, Adv. Biosciences, 1993, 87: 29-30
  8. PIZZOLATO G, BRIANI C, ROSSATO A., PONZA I, DAM M, CHIERICHETTI F., BORSATO N, FERLIN G, BATTISTIN L, SPECT imaging of the brain in dementia: follow-up evaluation , Adv. Biosciences, 1993, 87: 73-74
  9. FREO U, PIETRINI P, DANI A., GRADY C, SALERNO J, PIZZOLATO G, DAM M, BATTISTIN L, SHAPIRO MB, Cerebral glucose metabolism (rCMRglc) in demented patients with frontal lobe features assessed by high-resolution positron emission tomography (PET), Can. J. Neurol. Sci., 1993, 20 (suppl. 4): S165
  10. BATTISTIN L, ROSSATO A, BRIANI C, DAM M, BRACCO F, CHIERICHETTI F, FERLIN G, PIZZOLATO G, SPECT with the ligand 123I-iodobenzamide (IBZM) shows changes of striatal dopamine D2 receptor in fluctuating Parkinson's disease (PD) patients, Can. J. Neurol. Sci., 1993, 20 (suppl. 4): S166
  11. ROSSATO A, PIZZOLATO G, CAGNIN A, FABBRI M, DAM M, CHIERICHETTI F, BORSATO N, FERLIN G, BATTISTIN L, 123I-IBZM and 99mTc-HM-PAO SPET in Parkinson's disease (PD) and multiple system atrophy (MSA) patients, Ital. J. Neurol. Sci, 1993, suppl. 7: 31
  12. PIZZOLATO G, ROSSATO A, CAGNIN A, DAM, CHIERICHETTI F, FERLIN G, BATTISTIN L, SPECT studies in Parkinson's disease (PD), New Trends Clin. Neuropharmacol., 1993, 7: 88-89
  13. PIZOLATO G, ROSSATO A, CAGNIN A, DAM M, CHIERICHETTI F, FERLIN G, BATTISTIN, SPECT studies in Parkinson's disease, New Trends Clin. Neuropharmacol., 1994, 8: 27-28
  14. CAGNIN A, ROSSATO A, FABBRI M, DAM M, CHIERICHETTI F, BORSATO N, FERLIN G, PIZZOLATO G, BATTISTIN L, Chronic anticholinergic therapy affects cortical blood flow in Parkinson's disease: a 99mTc-HM-PAO SPET study, New Trends Clin. Neuropharmacol., 1994, 8: 145-146
  15. ROSSATO A, CAGNIN A, FABBRI M, DAM M, CHIERICHETTI F, BORSATO N, FERLIN G, PIZZOLATO G, BATTISTIN L, 123I-IBZM and 99mTc-HM-PAO SPET in progressive supranuclear palsy (PSP) and multiple system atrophy (MSA), New Trends Clin. Neuropharmacol., 1994, 8: 173-174
  16. DAM M, TONIN P, MILAN M, BRACCO F, MALESANI R, PIZZOLATO G, BATTISTIN L, Rehabilitation therapy in Parkionson's disease, New Trends Clin. Neuropharmacol., 1994, 8: 211
  17. CHIERICHETTI F, CASSON S, FABBRI M, CAGNIN A, DAM M, MENEGHELLO F, TONIN P, FERLIN G, BATTISTIN L, PIZZOLATO G, Cerebral perfusion study with HMPAO SPECT predicts long-term recovery after stroke, Acta Neurol. Belgica, 1995, Suppl.: 70
  18. PIZZOLATO G, CAGNIN A, DAM M, CHIERICHETTI F, FERLIN G, BATTISTIN L, Single photon emission tomography (SPET) assessment of parkinsonisms, J. Neural Transm, 1996, 103: V
Publications on Books
  1. FERLIN G, PIZZOLATO G, La SPET cerebrale con 99mTc-HM-PAO nella demenza e nel Morbo di Parkinson, in La SPET cerebrale con 99mTc-HM-PAO. Impiego clinico, Masson, 1993, 1: 49-70
  2. ROSSATO A, BRIANI C, CAGNIN A, PIZZOLATO G, DAM M, CHIERICHETTI F, BORSATO N, FERLIN G, BATTISTIN L, Contributo diagnostico dell'imaging funzionale cerebrale nella demenza, in Deterioramento delle funzioni cognitive e nuove ipotesi eziopatogenetiche, Excerpta medica, 1993, 1: 59-67

Reference
Scientific data
Publications
Products

Home page
 Products
No products

© CNR - Progetto Finalizzato Invecchiamento